219 related articles for article (PubMed ID: 10543411)
1. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.
Raptis SA; Hatziagelaki E; Dimitriadis G; Draeger KE; Pfeiffer C; Raptis AE
Exp Clin Endocrinol Diabetes; 1999; 107(6):350-5. PubMed ID: 10543411
[TBL] [Abstract][Full Text] [Related]
2. Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia.
Szoke E; Gosmanov NR; Sinkin JC; Nihalani A; Fender AB; Cryer PE; Meyer C; Gerich JE
Metabolism; 2006 Jan; 55(1):78-83. PubMed ID: 16324923
[TBL] [Abstract][Full Text] [Related]
3. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
4. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
5. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
6. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.
Müller G; Geisen K
Horm Metab Res; 1996 Sep; 28(9):469-87. PubMed ID: 8911985
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study.
Rave K; Flesch S; Kühn-Velten WN; Hompesch BC; Heinemann L; Heise T
Diabetes Metab Res Rev; 2005; 21(5):459-64. PubMed ID: 15915547
[TBL] [Abstract][Full Text] [Related]
9. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
Mauerhoff T; Ketelslegers JM; Lambert AE
Diabete Metab; 1986 Feb; 12(1):34-8. PubMed ID: 3084315
[TBL] [Abstract][Full Text] [Related]
10. Effects of glibenclamide on postprandial coagulation activation.
Ioannidis I; Tsoukala C; Panayotopoulou C; Skrapari I; Maglara E; Anastasopoulou Y; Mandalaki T; Katsilambros N
Nutr Metab Cardiovasc Dis; 1999 Aug; 9(4):204-7. PubMed ID: 10614063
[TBL] [Abstract][Full Text] [Related]
11. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of conventional sulfonylureas and glimepiride.
Geisen K; Végh A; Krause E; Papp JG
Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
[TBL] [Abstract][Full Text] [Related]
13. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
14. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
16. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
18. Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals.
Joy NG; Tate DB; Davis SN
Metabolism; 2015 Jun; 64(6):729-37. PubMed ID: 25765720
[TBL] [Abstract][Full Text] [Related]
19. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of three sulfonylureas on in vivo insulin action.
Sato J; Ohsawa I; Oshida Y; Fukuharu M; Hu XC; Tamagawa T; Sato Y
Arzneimittelforschung; 2001; 51(6):459-64. PubMed ID: 11455676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
